LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
企業コードLSB
会社名LakeShore Biopharma Co Ltd
上場日Jul 30, 2021
最高経営責任者「CEO」Mr. Dave Chenn
従業員数758
証券種類Ordinary Share
決算期末Jul 30
本社所在地- -
都市- -
証券取引所NASDAQ Capital Market Consolidated
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コードLSB
上場日Jul 30, 2021
最高経営責任者「CEO」Mr. Dave Chenn
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし